The ultimate goal of the Kittler Lab's research is to develop novel therapeutic approaches that target transcription factors, which play important roles in common solid tumors (brain, breast, lung and prostate cancer) and could therefore have translational potential.
We are broadly interested in understanding how resident intestinal microorganisms (particularly bacteria and fungi and collectively referred to as the gut microbiome) influence the health of human cancer and stem cell transplant patients.
The UT Larynx Lab is a collaboration between The University of Texas at Dallas and UT Southwestern. Our research focuses on the role of the larynx in vocal production and sensorimotor voice and breathing disorders.
The Lehrman lab uses biochemical approaches to study the functions of sugars and sugar-polymers coupled to proteins and lipids, and as free molecules. Our work involves broken-cell systems, living cultured cells, and animals. This area of research, known as Glycobiology, is an emerging field that encompasses most aspects of biology and medicine.
We are interested in understanding the process of co-evolution of tumor and immune cells during cancer development, which can be tracked from clonal expansion events, together with components of the tumor microenvironment and infiltrating immune repertoire.
The overarching goal of Wen-hong Li Lab is to investigate mechanisms responsible for maintaining islet cell function and to devise new strategies for enhancing beta cell fitness and robustness to prevent or treat diabetes.
Our lab lies in studying host-microbiota interactions in health and disease. Using innovative techniques in microbiology and immunology, and multiple model organisms (bacteria, fungi, drosophila, mice, and humans), his research aims to investigate the fundamental mechanisms by which gut commensal bacteria and fungi regulate local and systemic inflammatory immune responses.
Our mission is to understand the most fundamental questions in cancer biology, such as tumor initiation, progession, and response to therapy, through state-of-the-art experimentation, fruitful collaborations and, above all, out-of-the box thinking to develop novel, safe(r) and more effective therapies to win the fight against cancer!